Tazobactam/Piperacillinの呼吸器感染症に対する基礎的・臨床的研究
書誌事項
- タイトル別名
-
- Basic and clinical studies of tazobactam/piperacillin in respiratory infections
抄録
We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), which is tazobactam, a new β-lactamase inhibitor, combined with piperacillin, in respiratory infections, with the following results.<BR>The MICs of TAZ/PIPC against clinical isolates were determined with an inoculum size of 106 CFU/ml. The MIC90 was 3.13μg/ml for methicillin-sensitive Staphylococcus aureus, 1.56μg/ml for Streptococcus pneumoniae, 0.1μg/ml for Moraxella catarrhalis, 0.2μg/ml for Haemophilus influenzae, 25μg/ml for Klebsiella pneumoniae and 100μg/ml for Pseudomonas aeruginosa.<BR>The clinical evaluation of TAZ/PIPC in 5 patients with respiratory infections was excellent in 1, good in 3, unknown in 1. In all cases, neither side effects nor abnormal laboratory findings were observed.<BR>These results suggest that TAZ/PIPC is a useful antibacterial agent for respiratory infections.
収録刊行物
-
- CHEMOTHERAPY
-
CHEMOTHERAPY 42 (Supplement2), 433-436, 1994
公益社団法人 日本化学療法学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282681260805248
-
- NII論文ID
- 130004198595
-
- ISSN
- 18845894
- 00093165
-
- データソース種別
-
- JaLC
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可